Navigation Links
Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations

License with University of Pittsburgh Brings Additional Key Gene Locus as a

Development Opportunity for Recently-Funded Company

NEW HAVEN, Conn., Oct. 23 /PRNewswire/ -- Optherion, Inc., a company developing products to treat and diagnose dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system, announced today that it has licensed from the University of Pittsburgh the worldwide rights to develop diagnostic products for AMD associated with specific variations in genes on Chromosome 10.

Scientists at the University of Pittsburgh published in 2005 their findings of a link between Chromosome 10, specifically the LOC387715 and HTRA1 genes, and AMD, the leading cause of blindness in people over 60 in the developed world. Genetic tests that can identify people at risk of developing AMD, or that can predict the likely rate of progression and end-stage outcome of patients already diagnosed, should enable medical professionals to intervene more aggressively at an earlier stage with lifestyle changes and available therapies, thereby changing the course of disease.

AMD is caused by degeneration of the macula, the region of the retina responsible for central vision. AMD is unique in that it is a common disease that has recently been linked to common variations in only a few specific genes, presenting opportunities to develop both diagnostic tests and disease- modifying treatments. There are 15-20 million people with AMD in the U.S. and more than 50 million worldwide.

Optherion announced on October 9 that it had completed a $37 million financing. The Company was founded following scientific discoveries published in 2005 linking the role of Complement Factor H (CFH) and Complement Factor B (CFB) -- both regulators of the alternative complement pathway - to AMD. Three gene loci have been strongly linked to AMD: CFH, CFB, and specific variations on Chromosome 10. About half of patients with AMD suffer from variations in the CFH gene, while 74% of the disease can be explained by variations in the CFH and CFB genes combined. Variations associated with specific gene loci on Chromosome 10 in combination with CFH are associated with about 79% of the disease.

Colin J. Foster, President and CEO of Optherion, said: "The licensing agreement with the University of Pittsburgh adds significantly to our portfolio. Optherion is now in position to develop diagnostic tests based upon the most recently discovered genetic associations of dry AMD.

"We are optimistic that the innovative discoveries we are licensing will lead to diagnostic tests that can help change the current paradigm of AMD risk assessment and patient care," Mr. Foster added.

The finding that genetic variations on Chromosome 10 are implicated in AMD was published in the American Journal of Human Genetics by scientists from the University of Pittsburgh under the direction of Dr. Michael B. Gorin, an ophthalmologist whose career has been dedicated to studying the molecular genetics of hereditary eye diseases ("Susceptibility Genes for Age-Related Maculopathy on Chromosome 10q26," Johanna Jakobsdottir, Yvette P. Conley, Daniel E. Weeks, Tammy S. Mah, Robert E. Ferrell, and Michael B. Gorin (Am. J. Hum. Genet. 77:389-407, 2005)). Dr. Gorin in September 2006 became Professor of Ophthalmology and Harold and Pauline Price Chair in Ophthalmology at the Jules Stein Eye Institute at UCLA in Los Angeles.

Publications by other researchers have substantiated and replicated the links of CFH, CFB and Chromosome 10 to AMD. Additional research published in 2007 found that people with homozygous risk profiles for CFH, CFB and LOC387715/HTRA1 have as great as a 250 times increased risk of developing AMD.

About Optherion:

Optherion, Inc. is an early-stage biotechnology company that is developing products to treat and diagnose dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system. Optherion's proprietary technologies are based on recent scientific discoveries linking certain genes to AMD. Optherion has offices and laboratories in New Haven, CT., and on the biotechnology campus of the University of Iowa in Coralville, IA.

SOURCE Optherion, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. US Government Licenses New Hypertension Drug
2. Panacea Biotec In-Licenses FMD Vaccine
3. Thailand Goes Ahead With Licenses for Generic Drugs
4. Swedish Biotech Licenses HIV Drug to China for Development
5. More Foreign Trained Doctors Receive Licenses
6. FDA Licenses First US Vaccine Against Avian Flu
7. Thailand Will Not Issue Compulsory Licenses for Patented Drugs
8. Drop in Worldwide Measles deaths by 40%
9. Drugs Banned worldwide still available in India
10. Domestic Violence: The Silent Killer of Women Worldwide
11. New Study Questions Cannibalism As A Worldwide Selective Force
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
Breaking Medicine Technology: